MA43285A - Vecteurs cmv comprenant des éléments de reconnaissance des microarn - Google Patents
Vecteurs cmv comprenant des éléments de reconnaissance des microarnInfo
- Publication number
- MA43285A MA43285A MA043285A MA43285A MA43285A MA 43285 A MA43285 A MA 43285A MA 043285 A MA043285 A MA 043285A MA 43285 A MA43285 A MA 43285A MA 43285 A MA43285 A MA 43285A
- Authority
- MA
- Morocco
- Prior art keywords
- recognition elements
- vectors including
- cmv vectors
- including microrna
- microrna recognition
- Prior art date
Links
- 108091070501 miRNA Proteins 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16161—Methods of inactivation or attenuation
- C12N2710/16162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562258393P | 2015-11-20 | 2015-11-20 | |
US201662365259P | 2016-07-21 | 2016-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43285A true MA43285A (fr) | 2018-09-26 |
Family
ID=58719315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043285A MA43285A (fr) | 2015-11-20 | 2016-11-20 | Vecteurs cmv comprenant des éléments de reconnaissance des microarn |
Country Status (8)
Country | Link |
---|---|
US (2) | US10688164B2 (fr) |
EP (1) | EP3377636A4 (fr) |
JP (2) | JP7133468B2 (fr) |
CN (2) | CN108474003A (fr) |
AU (1) | AU2016355468B2 (fr) |
CA (1) | CA3005136A1 (fr) |
MA (1) | MA43285A (fr) |
WO (1) | WO2017087921A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011143653A2 (fr) | 2010-05-14 | 2011-11-17 | Oregon Health & Science University | Vecteurs recombinants du hcmv et du rhcmv, et leurs utilisations |
WO2012170765A2 (fr) | 2011-06-10 | 2012-12-13 | Oregon Health & Science University | Glycoprotéines de cmv et vecteurs recombinants cmv |
PL2964769T3 (pl) | 2013-03-05 | 2019-03-29 | Oregon Health & Science University | Wektory cytomegalowirusa umożliwiające kontrolę ukierunkowania limfocytów T |
EA039174B1 (ru) | 2014-07-16 | 2021-12-14 | Орегон Хелс Энд Сайенс Юниверсити | Цитомегаловирус человека, содержащий гетерологичный антиген, способ его получения, полинуклеотид, клетка, композиция и способ индуцирования иммунного ответа (варианты) |
BR112017017092A2 (pt) | 2015-02-10 | 2018-06-26 | Univ Oregon Health & Science | métodos e composições úteis na geração de respostas de células t cd8+ não canônicas |
CN108474003A (zh) | 2015-11-20 | 2018-08-31 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
US11091775B2 (en) | 2016-06-22 | 2021-08-17 | Oregon Health And Science University | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
MA46588A (fr) | 2016-10-18 | 2021-04-14 | Univ Oregon Health & Science | Vecteurs de cytomégalovirus déclenchant des lymphocytes t limités par des molécules e de complexe majeur d'histocompatibilité |
GB201714430D0 (en) * | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
EP3697806A4 (fr) | 2017-10-17 | 2021-10-27 | International AIDS Vaccine Initiative, Inc. | Cassettes d'antigènes de la tuberculose |
EP3980071A4 (fr) * | 2019-06-07 | 2023-10-11 | Oregon Health & Science University | Réponses de lymphocytes t spécifiques d'un antigène associé à une tumeur |
CR20220093A (es) | 2019-08-20 | 2022-06-15 | Univ Oregon Health & Science | Modulación de las respuestas de células t por ul18 del citomegalovirus humano |
WO2023034801A1 (fr) | 2021-08-31 | 2023-03-09 | Vir Biotechnology, Inc. | Vecteurs de hcmv recombinants et leurs utilisations |
IL310667A (en) | 2021-08-31 | 2024-04-01 | Vir Biotechnology Inc | Tuberculosis vaccines |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
EP0319570B1 (fr) | 1987-06-26 | 1995-02-22 | Syntro Corporation | Cytomegalovirus humain recombinant contenant des genes etrangers et son utilisation |
US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
CA2089666C (fr) * | 1990-08-16 | 2003-01-07 | Kevin P. Anderson | Oligonucleotides pour moduler les effets des infections a cytomegalovirus |
EP0521427A1 (fr) | 1991-07-05 | 1993-01-07 | American Cyanamid Company | Méthode d'identification de genes non-essentiels de cytomégalovirus humain, et de criblage d'inhibiteurs de cytomégalovirus humain |
WO1995003399A2 (fr) | 1993-07-19 | 1995-02-02 | Cantab Pharmaceuticals Research Limited | Procede de production destine a la preparation de virus neutralises |
EP0758396B1 (fr) | 1994-04-29 | 2006-07-26 | Pharmacia & Upjohn Company LLC | Vaccin contre le virus de l'immunodeficience feline |
US5846806A (en) | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
ES2264136T3 (es) | 1995-02-21 | 2006-12-16 | Cantab Pharmaceuticals Research Limited | Preparaciones virales, vectores, inmunogenos y sus vacunas. |
KR19980703665A (ko) | 1995-04-04 | 1998-12-05 | 카렌 크루벤 | 세포 표면상 제 1 류 mhc 단백질의 수준이 낮은 유전적으로변형된 세포의 이식 |
DE69732498T2 (de) | 1996-07-31 | 2006-04-27 | Ortho-Mcneil Pharmaceutical, Inc. | Erkennung von menschlichen cytomegalovirus genes, welche die expression von mhc klasse i schweren ketten erniedrigen |
US20030138454A1 (en) | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
DE19733364A1 (de) | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
WO1999007869A1 (fr) | 1997-08-05 | 1999-02-18 | University Of Florida | Vaccin vivant recombinant comprenant un virus ne se repliquant pas ou se repliquant sans efficacite |
US6884785B2 (en) * | 1999-06-17 | 2005-04-26 | The Scripps Research Institute | Compositions and methods for the treatment or prevention of autoimmune diabetes |
US7204990B1 (en) | 2000-11-28 | 2007-04-17 | Medimmune Vaccines, Inc. | Attenuation of cytomegalovirus virulence |
US6740324B2 (en) | 2001-02-02 | 2004-05-25 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
WO2002066629A2 (fr) | 2001-02-21 | 2002-08-29 | Gabriele Hahn | Vecteur de recombinaison contenant le genome infectieux du cytomegalovirus humain, conservant les caracteristiques de type sauvage d'isolats cliniques |
GB0122232D0 (en) | 2001-09-14 | 2001-11-07 | Medical Res Council | Gene expression |
BR0212619A (pt) | 2001-09-20 | 2004-08-17 | Glaxo Group Ltd | Sequência de nucleotìdeo, vetor, proteìna, composição farmacêutica, dispositivo de liberação intradérmica, método para tratar um paciente que sofre de uma doença ou é suscetìvel a ela, uso de uma sequência de nucleotìdeo, e, processo para a produção de um nucleotìdeo |
US20030118568A1 (en) | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
WO2003093455A2 (fr) | 2002-04-30 | 2003-11-13 | Avior Therapeutics, Inc. | Vecteurs d'adenovirus utilises en immunotherapie |
DE10232322A1 (de) | 2002-07-16 | 2004-07-29 | Hahn, Gabriele, Dr. | Viral kodierte CxC determinieren den Gewebetropismus von HCMV |
US7407744B2 (en) | 2003-07-25 | 2008-08-05 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-CMV vaccines, and CMV-based vectors |
CA2567597C (fr) | 2004-05-25 | 2014-03-18 | Oregon Health And Science University | Vaccination du virus de l'immunodeficience simienne (siv) et du virus de l'immunodeficience humaine (vih) utilisant des vecteurs de vaccin a base de rhcmv et hcmv |
EP1602676A1 (fr) | 2004-06-01 | 2005-12-07 | SOLVAY (Société Anonyme) | Compositions catalytiques |
WO2006004661A1 (fr) | 2004-06-25 | 2006-01-12 | Medimmune Vaccines, Inc. | Cytomegalovirus humain de recombinaison et vaccins contenant des antigenes heterologues |
WO2006125983A1 (fr) | 2005-05-23 | 2006-11-30 | Oxxon Therapeutics Ltd | Compositions permettant d'induire une reponse immunitaire contre l'hepatite b |
WO2007027860A2 (fr) | 2005-08-31 | 2007-03-08 | Genvec, Inc. | Vaccins contre la malaria a base de vecteurs adenoviraux |
WO2008112146A2 (fr) | 2007-03-07 | 2008-09-18 | The Trustees Of The University Of Pennsylvania | Imagerie partiellement parallèle en 2d avec reconstruction de données basée sur des voisins environnants d'espace k |
BRPI0814060A2 (pt) | 2007-07-06 | 2015-01-06 | Trubion Pharmaceuticals Inc | Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal |
PE20091434A1 (es) | 2007-10-30 | 2009-10-17 | Genentech Inc | Purificacion de anticuerpos por cromatografia de intercambio cationico |
US8074351B2 (en) * | 2008-07-25 | 2011-12-13 | Panasonic Corporation | Part mounting device and part mounting method |
US8883995B2 (en) | 2009-03-06 | 2014-11-11 | Icahn School Of Medicine At Mount Sinai | Live attenuated influenza virus vaccines comprising microRNA response elements |
AU2010334809C1 (en) | 2009-12-23 | 2015-02-26 | Agenus Inc. | Binding members for human cytomegalovirus |
EP2529227B1 (fr) | 2010-01-27 | 2015-10-07 | Oregon Health & Science University | Préparations immunogènes à base de cytomégalovirus |
EP2550362B1 (fr) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Glycoprotéines du cmv et vecteurs recombinés |
US9078867B2 (en) | 2010-05-05 | 2015-07-14 | Christian Thirion | Vaccine against beta-herpesvirus infection and use thereof |
WO2011143653A2 (fr) | 2010-05-14 | 2011-11-17 | Oregon Health & Science University | Vecteurs recombinants du hcmv et du rhcmv, et leurs utilisations |
WO2012170765A2 (fr) | 2011-06-10 | 2012-12-13 | Oregon Health & Science University | Glycoprotéines de cmv et vecteurs recombinants cmv |
US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
JP6419706B2 (ja) * | 2012-10-25 | 2018-11-07 | トカジェン インコーポレーテッド | ミニプロモーターカセットを含むレトロウイルスベクター |
US8903341B2 (en) | 2012-12-05 | 2014-12-02 | Qualcomm Incorporated | Successive interference cancellation (SIC) ordering algorithms for improved multiple-input multiple-output (MIMO) performance |
PL2964769T3 (pl) | 2013-03-05 | 2019-03-29 | Oregon Health & Science University | Wektory cytomegalowirusa umożliwiające kontrolę ukierunkowania limfocytów T |
EA039174B1 (ru) | 2014-07-16 | 2021-12-14 | Орегон Хелс Энд Сайенс Юниверсити | Цитомегаловирус человека, содержащий гетерологичный антиген, способ его получения, полинуклеотид, клетка, композиция и способ индуцирования иммунного ответа (варианты) |
EP3048114A1 (fr) | 2015-01-22 | 2016-07-27 | Novartis AG | Antigènes du cytomégalovirus et leurs utilisations |
BR112017017092A2 (pt) | 2015-02-10 | 2018-06-26 | Univ Oregon Health & Science | métodos e composições úteis na geração de respostas de células t cd8+ não canônicas |
CN108474003A (zh) | 2015-11-20 | 2018-08-31 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
US11091775B2 (en) | 2016-06-22 | 2021-08-17 | Oregon Health And Science University | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
MA45455A (fr) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Procédé d'identification d'épitopes peptidiques, molécules qui se lient à de tels épitopes et utilisations associées |
MA46588A (fr) | 2016-10-18 | 2021-04-14 | Univ Oregon Health & Science | Vecteurs de cytomégalovirus déclenchant des lymphocytes t limités par des molécules e de complexe majeur d'histocompatibilité |
-
2016
- 2016-11-20 CN CN201680075638.9A patent/CN108474003A/zh active Pending
- 2016-11-20 WO PCT/US2016/062973 patent/WO2017087921A1/fr active Application Filing
- 2016-11-20 EP EP16867316.8A patent/EP3377636A4/fr active Pending
- 2016-11-20 CN CN202310470923.2A patent/CN116926128A/zh active Pending
- 2016-11-20 JP JP2018526190A patent/JP7133468B2/ja active Active
- 2016-11-20 AU AU2016355468A patent/AU2016355468B2/en active Active
- 2016-11-20 CA CA3005136A patent/CA3005136A1/fr active Pending
- 2016-11-20 MA MA043285A patent/MA43285A/fr unknown
- 2016-11-20 US US15/356,627 patent/US10688164B2/en active Active
-
2020
- 2020-05-08 US US16/870,766 patent/US20200368333A1/en not_active Abandoned
-
2022
- 2022-08-29 JP JP2022135565A patent/JP2022174123A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200368333A1 (en) | 2020-11-26 |
JP7133468B2 (ja) | 2022-09-08 |
EP3377636A4 (fr) | 2019-11-06 |
US10688164B2 (en) | 2020-06-23 |
AU2016355468B2 (en) | 2022-12-15 |
CA3005136A1 (fr) | 2017-05-26 |
WO2017087921A1 (fr) | 2017-05-26 |
AU2016355468A1 (en) | 2018-05-31 |
JP2022174123A (ja) | 2022-11-22 |
CN108474003A (zh) | 2018-08-31 |
EP3377636A1 (fr) | 2018-09-26 |
JP2019502371A (ja) | 2019-01-31 |
US20170143809A1 (en) | 2017-05-25 |
CN116926128A (zh) | 2023-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43285A (fr) | Vecteurs cmv comprenant des éléments de reconnaissance des microarn | |
IL279154B (en) | Adenovirus-related vector | |
GB201401707D0 (en) | Adeno-associated viral vectors | |
HUE041629T2 (hu) | Festõegység | |
IL234766A (en) | Fluorescent Imaging System | |
GB2539220B (en) | Canvas system | |
HUE051749T2 (hu) | Labirintusgomba mikroorganizmusokból származó szabályozó elemek | |
IL259964A (en) | Adenovirus-associated vectors for the treatment of mucolipodosis type ii | |
PL3192358T3 (pl) | System hodowli norek | |
GB2539061B (en) | Comb | |
GB2543858B (en) | Authentication system | |
GB2547622B (en) | Excitation system | |
GB201505332D0 (en) | Authentication system | |
GB2542888B (en) | Fingerprint imaging | |
GB201610484D0 (en) | Novel dyeing system | |
GB201610448D0 (en) | Adeno-associated viral vector system | |
GB201603064D0 (en) | Peg cover | |
HK1217864A2 (zh) | 髮梳 | |
GB201523164D0 (en) | Drying system | |
GB201522855D0 (en) | Recruitment consultancy & HR consultancy services | |
HU4596U (en) | Axial fan cover increased construction | |
ES1149238Y (es) | Estuche barajador de naipes. | |
GB201515999D0 (en) | Authentication system | |
GB201506498D0 (en) | Biometric system | |
ITUB20151906A1 (it) | Fionda. |